Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Published:2013-10 Issue:11 Volume:14 Page:1055-1066
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Miguel Jesus San,Weisel Katja,Moreau Philippe,Lacy Martha,Song Kevin,Delforge Michel,Karlin Lionel,Goldschmidt Hartmut,Banos Anne,Oriol Albert,Alegre Adrian,Chen Christine,Cavo Michele,Garderet Laurent,Ivanova Valentina,Martinez-Lopez Joaquin,Belch Andrew,Palumbo Antonio,Schey Stephen,Sonneveld Pieter,Yu Xin,Sternas Lars,Jacques Christian,Zaki Mohamed,Dimopoulos Meletios

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib therapy: a multicentre International Myeloma Working Group study;Kumar;Leukemia,2012

2. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma;Quach;Leukemia,2010

3. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus lowdose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI);Matous;J Clin Oncol,2013

4. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma;Schey;J Clin Oncol,2004

5. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation;Streetly;Br J Haematol,2008

Cited by 676 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial;Nature Medicine;2024-01-04

2. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial;Annals of Hematology;2023-12-19

3. Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report;Oncohematology;2023-12-08

4. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?;Life;2023-11-20

5. Relapsed/Refractory Multiple Myeloma;Cancer Consult;2023-11-18